Tumor necrosis factor-α blockade for the treatment of acute GVHD

Daniel Couriel, Rima Saliba, Krystal Hicks, Cindy Ippoliti, Marcos De Lima, Chitra Hosing, Issa Khouri, Borje Andersson, James Gajewski, Michele Donato, Paolo Anderlini, Dimitrios P. Kontoyiannis, Agueda Cohen, Thomas Martin, Sergio Giralt, Richard Champlin

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Despite posttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major cause of sickness and death. Tumor necrosis factor-α (TNF-α) is implicated in the pathophysiology of GVHD at several steps in the process. Infliximab is a genetically constructed immunoglobulin G1 (IgG1) murine-human chimeric monoclonal antibody that binds the soluble subunit and the membrane-bound precursor of TNF-α, blocking its interaction with receptors and causing lysis of cells that produce TNF-α. In this study we retrospectively evaluated 134 patients who had steroid-refractory acute GVHD. Of these, 21 who received infliximab as a single agent were analyzed. The overall response rate was 67% (n = 14), and 13 patients (62%) experienced complete response (CR). Five patients (24%) did not respond, and 2 (10%) had progressive GVHD. None had a toxic reaction to infliximab. Ten patients (48%) had 18 fungal infections, including Aspargillus species in 7 and Candida species in 10. Seventeen patients (81%) had bacterial infections, including 32 gram-positive and 8 gram-negative infections. Viral infections, primarily cytomegalovirus reactivation, occurred in 14 patients (67%). The Kaplan-Meier estimate of-overall survival was 38%. In conclusion, infliximab was well tolerated and active for the treatment of steroid-resistant acute GVHD, particularly with gastrointestinal tract involvement. Survival after steroid-resistant acute GVHD continues to be problematic. The possibility of excessive fungal and other infections must be explored further.

Original languageEnglish (US)
Pages (from-to)649-654
Number of pages6
JournalBlood
Volume104
Issue number3
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Graft vs Host Disease
Grafts
Tumor Necrosis Factor-alpha
Mycoses
Steroids
Therapeutics
Survival
Candida
Poisons
Kaplan-Meier Estimate
Virus Diseases
Immunosuppressive Agents
Cytomegalovirus
Bacterial Infections
Refractory materials
Gastrointestinal Tract
Immunoglobulins
Cause of Death
Monoclonal Antibodies
Membranes

ASJC Scopus subject areas

  • Hematology

Cite this

Couriel, D., Saliba, R., Hicks, K., Ippoliti, C., De Lima, M., Hosing, C., ... Champlin, R. (2004). Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood, 104(3), 649-654. https://doi.org/10.1182/blood-2003-12-4241

Tumor necrosis factor-α blockade for the treatment of acute GVHD. / Couriel, Daniel; Saliba, Rima; Hicks, Krystal; Ippoliti, Cindy; De Lima, Marcos; Hosing, Chitra; Khouri, Issa; Andersson, Borje; Gajewski, James; Donato, Michele; Anderlini, Paolo; Kontoyiannis, Dimitrios P.; Cohen, Agueda; Martin, Thomas; Giralt, Sergio; Champlin, Richard.

In: Blood, Vol. 104, No. 3, 01.08.2004, p. 649-654.

Research output: Contribution to journalArticle

Couriel, D, Saliba, R, Hicks, K, Ippoliti, C, De Lima, M, Hosing, C, Khouri, I, Andersson, B, Gajewski, J, Donato, M, Anderlini, P, Kontoyiannis, DP, Cohen, A, Martin, T, Giralt, S & Champlin, R 2004, 'Tumor necrosis factor-α blockade for the treatment of acute GVHD', Blood, vol. 104, no. 3, pp. 649-654. https://doi.org/10.1182/blood-2003-12-4241
Couriel D, Saliba R, Hicks K, Ippoliti C, De Lima M, Hosing C et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood. 2004 Aug 1;104(3):649-654. https://doi.org/10.1182/blood-2003-12-4241
Couriel, Daniel ; Saliba, Rima ; Hicks, Krystal ; Ippoliti, Cindy ; De Lima, Marcos ; Hosing, Chitra ; Khouri, Issa ; Andersson, Borje ; Gajewski, James ; Donato, Michele ; Anderlini, Paolo ; Kontoyiannis, Dimitrios P. ; Cohen, Agueda ; Martin, Thomas ; Giralt, Sergio ; Champlin, Richard. / Tumor necrosis factor-α blockade for the treatment of acute GVHD. In: Blood. 2004 ; Vol. 104, No. 3. pp. 649-654.
@article{091cdbf10a8242e8bda6e341945f8081,
title = "Tumor necrosis factor-α blockade for the treatment of acute GVHD",
abstract = "Despite posttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major cause of sickness and death. Tumor necrosis factor-α (TNF-α) is implicated in the pathophysiology of GVHD at several steps in the process. Infliximab is a genetically constructed immunoglobulin G1 (IgG1) murine-human chimeric monoclonal antibody that binds the soluble subunit and the membrane-bound precursor of TNF-α, blocking its interaction with receptors and causing lysis of cells that produce TNF-α. In this study we retrospectively evaluated 134 patients who had steroid-refractory acute GVHD. Of these, 21 who received infliximab as a single agent were analyzed. The overall response rate was 67{\%} (n = 14), and 13 patients (62{\%}) experienced complete response (CR). Five patients (24{\%}) did not respond, and 2 (10{\%}) had progressive GVHD. None had a toxic reaction to infliximab. Ten patients (48{\%}) had 18 fungal infections, including Aspargillus species in 7 and Candida species in 10. Seventeen patients (81{\%}) had bacterial infections, including 32 gram-positive and 8 gram-negative infections. Viral infections, primarily cytomegalovirus reactivation, occurred in 14 patients (67{\%}). The Kaplan-Meier estimate of-overall survival was 38{\%}. In conclusion, infliximab was well tolerated and active for the treatment of steroid-resistant acute GVHD, particularly with gastrointestinal tract involvement. Survival after steroid-resistant acute GVHD continues to be problematic. The possibility of excessive fungal and other infections must be explored further.",
author = "Daniel Couriel and Rima Saliba and Krystal Hicks and Cindy Ippoliti and {De Lima}, Marcos and Chitra Hosing and Issa Khouri and Borje Andersson and James Gajewski and Michele Donato and Paolo Anderlini and Kontoyiannis, {Dimitrios P.} and Agueda Cohen and Thomas Martin and Sergio Giralt and Richard Champlin",
year = "2004",
month = "8",
day = "1",
doi = "10.1182/blood-2003-12-4241",
language = "English (US)",
volume = "104",
pages = "649--654",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Tumor necrosis factor-α blockade for the treatment of acute GVHD

AU - Couriel, Daniel

AU - Saliba, Rima

AU - Hicks, Krystal

AU - Ippoliti, Cindy

AU - De Lima, Marcos

AU - Hosing, Chitra

AU - Khouri, Issa

AU - Andersson, Borje

AU - Gajewski, James

AU - Donato, Michele

AU - Anderlini, Paolo

AU - Kontoyiannis, Dimitrios P.

AU - Cohen, Agueda

AU - Martin, Thomas

AU - Giralt, Sergio

AU - Champlin, Richard

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Despite posttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major cause of sickness and death. Tumor necrosis factor-α (TNF-α) is implicated in the pathophysiology of GVHD at several steps in the process. Infliximab is a genetically constructed immunoglobulin G1 (IgG1) murine-human chimeric monoclonal antibody that binds the soluble subunit and the membrane-bound precursor of TNF-α, blocking its interaction with receptors and causing lysis of cells that produce TNF-α. In this study we retrospectively evaluated 134 patients who had steroid-refractory acute GVHD. Of these, 21 who received infliximab as a single agent were analyzed. The overall response rate was 67% (n = 14), and 13 patients (62%) experienced complete response (CR). Five patients (24%) did not respond, and 2 (10%) had progressive GVHD. None had a toxic reaction to infliximab. Ten patients (48%) had 18 fungal infections, including Aspargillus species in 7 and Candida species in 10. Seventeen patients (81%) had bacterial infections, including 32 gram-positive and 8 gram-negative infections. Viral infections, primarily cytomegalovirus reactivation, occurred in 14 patients (67%). The Kaplan-Meier estimate of-overall survival was 38%. In conclusion, infliximab was well tolerated and active for the treatment of steroid-resistant acute GVHD, particularly with gastrointestinal tract involvement. Survival after steroid-resistant acute GVHD continues to be problematic. The possibility of excessive fungal and other infections must be explored further.

AB - Despite posttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major cause of sickness and death. Tumor necrosis factor-α (TNF-α) is implicated in the pathophysiology of GVHD at several steps in the process. Infliximab is a genetically constructed immunoglobulin G1 (IgG1) murine-human chimeric monoclonal antibody that binds the soluble subunit and the membrane-bound precursor of TNF-α, blocking its interaction with receptors and causing lysis of cells that produce TNF-α. In this study we retrospectively evaluated 134 patients who had steroid-refractory acute GVHD. Of these, 21 who received infliximab as a single agent were analyzed. The overall response rate was 67% (n = 14), and 13 patients (62%) experienced complete response (CR). Five patients (24%) did not respond, and 2 (10%) had progressive GVHD. None had a toxic reaction to infliximab. Ten patients (48%) had 18 fungal infections, including Aspargillus species in 7 and Candida species in 10. Seventeen patients (81%) had bacterial infections, including 32 gram-positive and 8 gram-negative infections. Viral infections, primarily cytomegalovirus reactivation, occurred in 14 patients (67%). The Kaplan-Meier estimate of-overall survival was 38%. In conclusion, infliximab was well tolerated and active for the treatment of steroid-resistant acute GVHD, particularly with gastrointestinal tract involvement. Survival after steroid-resistant acute GVHD continues to be problematic. The possibility of excessive fungal and other infections must be explored further.

UR - http://www.scopus.com/inward/record.url?scp=3242756749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242756749&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-12-4241

DO - 10.1182/blood-2003-12-4241

M3 - Article

C2 - 15069017

AN - SCOPUS:3242756749

VL - 104

SP - 649

EP - 654

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -